HYPHENS PHARMA INTL LIMITED (SGX:1J5)
Hyphen Pharma International - Receives S$6m Fund Infusion, Digital Assets Valued At S$60m
- Hyphens Pharma (SGX:1J5) received a S$6m fund infusion for a 10% stake in its digital assets under DocMed Technology. The fund will be used to further develop its existing digital infrastructure into an integrated healthtech platform. About 50% of the proceeds will be used to expand into Malaysia, Vietnam and other ASEAN countries.
DocMed Technology
- DocMed has three verticals:
- Wholesale of pharmaceuticals and medical supplies in Singapore through Pan-Malayan, a B2B medical hypermart for healthcare professionals, institutions and retail pharmacies. It runs www.pom.com.sg which is a platform for brand principals to provide product information and educational materials to medical professionals;
- WellAway, a B2C digital platform for doctors to give e-prescriptions and have the prescribed medicines delivered directly to the patients’ homes. WellAway holds the only e-pharmacy licence issued by the Health Science Authority in Singapore; and
- DocCentral, which offers a suite of tools for medical professionals to collaborate, network, conduct virtual patient visits and coordinate patient care.
Fund injection positive for Hyphens.
- The fund injection is positive for Hyphens Pharma and 147% for EBITDA, and guided 32% revenue and 28% EBITDA growth for FY23E.
Raised Hyphens Pharma's target price to S$0.46.
- DocMed will incur higher outlay in FY22E and FY23E for recruitment and roll-out into the regional price for Hyphens Pharma to S$0.46 (COE: 14%).
- See
Peggy Mak
SAC Capital Research
|
https://www.saccapital.com.sg/
2022-06-06
SGX Stock
Analyst Report
0.460
UP
0.400
